Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertising
UsernamePublicRestriction

BioCryst Pharmaceuticals Inc.

www.biocryst.com

Latest From BioCryst Pharmaceuticals Inc.

Bookmark
  • News

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End

By Maureen Kenny

Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.

Europe Approvals
Bookmark
  • News

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

By John Davis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch
Bookmark
  • News

FDA Approval Round Up: Keytruda, Opdivo Add Claims

By Michael Cipriano

Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.

Drug Review Approvals
Bookmark
  • Analysis

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

By John Davis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioCryst Pharmaceuticals Inc.
  • Senior Management
  • Jon P Stonehouse, Pres. & CEO
    Thomas R Staab, SVP, CFO
    William P Sheridan, SVP, CMO
    Lynne Powell, SVP, Chief Commercial Officer
  • Contact Info
  • BioCryst Pharmaceuticals Inc.
    Phone: (919) 859-1302
    4505 Emperor Blvd., Ste. 200
    Durham, NC 27703
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By